Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
After a long delay, Momenta $MNTA and Novartis $NVS have finally received an FDA green light for its Copaxone copycat, catching up with Mylan in slicing shares of the multiple sclerosis market from struggling Teva.
Sandoz, the generics unit of the Swiss giant, and Cambridge, MA-based Momenta promptly announced a US launch of the 40 mg/ml dose early Tuesday, right as they celebrate the win. A lower dosage (20 mg/ml) of the drug is already available commercially, but it is the 40 mg/ml version that competes directly with Teva’s blockbuster drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
